Glycemic variability

Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin...

Descripción completa

Detalles Bibliográficos
Autores: Fuentes, Blanca|||0000-0002-0363-862X, Pastor-Yborra, Silvia, Gutiérrez-Zúñiga, Raquel, González-Pérez de Villar, Noemí, de Celis, Elena, Rodríguez-Pardo, Jorge, Gómez-de Frutos, Mari Carmen, Laso-García, Fernando, Gutiérrez-Fernández, María, Ortega-Casarrubios, MÁngeles, Soto, Alfonso, López-Fernández, María, Santamaría, María, Díez-González, Noemí, Freijo, Mar M., Zandio, Beatriz, Delgado Mederos, Raquel|||0000-0003-3737-7226, Calleja, Ana, Portilla-Cuenca, Juan Carlos, Lisbona, Arturo, Otero-Ortega, Laura, Díez-Tejedor, Exuperio
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:253053
Acceso en línea:https://ddd.uab.cat/record/253053
https://dx.doi.org/urn:doi:10.1186/s12967-020-02586-4
Access Level:acceso abierto
Palabra clave:Ischemic stroke
Glycemic variability
Insulin
Outcomes
Translational research
Descripción
Sumario:Glycemic variability (GV) represents the amplitude of oscillations in glucose levels over time and is associated with higher mortality in critically ill patients. Our aim is to evaluate the impact of GV on acute ischemic stroke (IS) outcomes in humans and explore the impact of two different insulin administration routes on GV in an animal model. This translational study consists of two studies conducted in parallel: The first study is an observational, multicenter, prospective clinical study in which 340 patients with acute IS will be subcutaneously implanted a sensor to continuously monitor blood glucose levels for 96 h. The second study is a basic experimental study using an animal model (rats) with permanent occlusion of the middle cerebral artery and induced hyperglycemia (through an intraperitoneal injection of nicotinamide and streptozotocin). The animal study will include the following 6 groups (10 animals per group): sham; hyperglycemia without IS; IS without hyperglycemia; IS and hyperglycemia without treatment; IS and hyperglycemia and intravenous insulin; and IS and hyperglycemia and subcutaneous insulin. The endpoint for the first study is mortality at 3 months, while the endpoints for the animal model study are GV, functional recovery and biomarkers. The GLIAS-III study will be the first translational approach analyzing the prognostic influence of GV, evaluated by the use of subcutaneous glucose monitors, in acute stroke. Trial registration (NCT04001049).

Similares en LA Referencia